NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
Clinical Trials
343 trialsNCT04256421 2026-01-28
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT04640480 2026-01-27
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Phase 1 Completed
NCT00213798 2025-12-22
Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients
University Hospital, Strasbourg, France
Phase NA Completed
NCT03595059 2025-12-10
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
Phase 1 Completed
NCT04063163 2025-12-09
A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC
Shanghai Henlius Biotech
Phase 3 Completed
NCT05329623 2025-10-10
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
Novartis
Phase 1 Completed
NCT04885998 2025-09-29
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
Amgen
Phase 1 Completed
NCT02514447 2025-09-25
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
G1 Therapeutics, Inc.
Phase 1/2 Completed
NCT03041311 2025-09-25
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
Phase 2 Completed
NCT05509699 2025-08-29
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT03708328 2025-08-20
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT07132957 2025-08-20
A Study of AL8326 in Healthy Subjects
Advenchen Laboratories, LLC
Phase 1 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02769832 2025-07-29
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
University of Iowa
Phase 2 Completed
NCT02769962 2025-07-28
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04242199 2025-07-14
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT03382561 2025-07-03
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT05253053 2025-06-12
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1/2 Completed
NCT04358237 2025-06-04
LUPER
Blanco, Dr Antonio Calles MD
Phase 1/2 Completed
NCT04314895 2025-05-23
Trial of NanoPac Intratumoral Injection in Lung Cancer
NanOlogy, LLC
Phase 2 Completed
NCT04774380 2025-05-23
LUMINANCE
AstraZeneca
Phase 3 Completed
NCT02487095 2025-04-13
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02922764 2025-03-26
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
Phase 1 Completed
NCT04209595 2025-03-17
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05619744 2025-03-10
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Hoffmann-La Roche
Phase 1 Completed
NCT04005716 2025-02-28
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT02349412 2025-02-07
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03532880 2025-02-07
A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01703481 2025-02-03
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Janssen Research & Development, LLC
Phase 1 Completed
NCT04350463 2025-01-22
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Celgene
Phase 2 Completed
NCT05309629 2025-01-17
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT04012606 2025-01-16
Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT03043599 2024-12-20
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT04830813 2024-12-09
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Chipscreen Biosciences, Ltd.
Phase 3 Completed
NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
NCT05712889 2024-11-15
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Phase 1 Completed
NCT02046733 2024-11-08
STIMULI
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT04504669 2024-11-05
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT05304793 2024-10-31
Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT03958045 2024-10-22
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
University of Kentucky
Phase 2 Completed
NCT01306045 2024-10-01
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04768296 2024-09-26
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
EMD Serono
Phase 2 Completed
NCT00686985 2024-09-20
DOCAR
Jeroen Bosch Ziekenhuis
Phase 2 Completed
NCT04434482 2024-09-19
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Impact Therapeutics, Inc.
Phase 1/2 Completed
NCT05002868 2024-09-19
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
Rhizen Pharmaceuticals SA
Phase 1 Completed